Pharmacologic treatments for covid-19 patients
Methylprednisolone vs Dexamethasone
This comparison will not be updated. Last search date 14 Dec, 2022.
Studies included but not extracted/included in the analysis: Salton F, Eur Respir J, 2022; Corral-Gudino L, Eur J Clin Invest, 2022
Hospitalized patients
Forest plots
(last update: 2022-08-04)
Summary of findings
(last update: 2022-09-27)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=231
Back to your research
Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
---|---|---|---|---|---|---|---|---|
Treatment 1 | Treatment 2 | |||||||
IRCT20210223050466N1 Dastenae ZH, Int J Infect Dis, 2022 Full text Commentary Commentary |
Public/non profit |
Methylprednisolone |
Dexamethasone |
RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to a single center in Iran. | N=143 |
Some concerns Details |
|
IRCT20200204046369N1 Ranjbar K, BMC Infect Dis, 2021 Full text Commentary Commentary |
Public/non profit |
Methylprednisolone |
Dexamethasone |
RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a single center in Iran | N=93 |
Some concerns Details |